EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Multidrug resistant non-small cell lung cancer cells exhibiting collateral sensitivity to DNA damaging drugs

Sara Peixoto da Silva, Lúcio Lara Santos, Cristina P R Xavier, M Helena Vasconcelos

Life Sciences · 2026

DOI: 10.1016/j.lfs.2026.124273 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life Sciences, 2026. Verfasst von Sara Peixoto da Silva und 3 weiteren Autor:innen. Beteiligte Einrichtung: i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal; Department of Biological Sciences, Faculty of Pharmacy o…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Lung Neoplasms, DNA Damage. Die Arbeit nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação para a Ciência e a Tecnologia, European Regional Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIM: Multidrug resistance (MDR) severely limits the efficacy of non-small lung cancer (NSCLC) treatment. Counteracting MDR is very difficult but highly necessary to extend the survival of MDR patients. This work aimed at establishing MDR NSCLC cellular models, to identify mechanisms responsible for their resistance to several treatments and new collateral sensitivity approaches to overcome MDR. METHODS: Two paclitaxel resistant cell sublines (A549-CDR1 and A549-CDR2) were established, by treating A549 cells with increasing concentrations of paclitaxel. The proteomic profile (liquid chromatography-mass spectrometry) of these sublines was assessed as well as their MDR phenotype by evaluating response to several chemotherapeutic drugs (Sulforhodamine B assay) and the expression levels (Western Blotting) and activity (Rhodamine-123 accumulation assay) of ATP-binding cassette (ABC) transporter proteins. Cell death, reactive oxygen species (ROS) production (flow cytometry) and DNA damage levels (Comet assay and Western Blotting) were also evaluated prior to and following treatments with several drugs. KEY FINDINGS: The two established paclitaxel resistant cell sublines exhibited distinct proteomic profiles, although both presented a MDR phenotype, confirmed by cross-resistance to other chemotherapeutic drugs and increased expression levels and activity of ABC transporter proteins. They presented lower proliferation, higher ROS levels and increased DNA damage levels. These MDR cells were more sensitive than their parental cells to DNA damaging drugs that are not P-glycoprotein (P-gp) substrates, thus presenting collateral sensitivity to such drugs. SIGNIFICANCE: The established NSCLC MDR cell lines are promising models to understanding mechanisms associated with MDR and exploiting collateral sensitivity approaches to overcome MDR in NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmLung NeoplasmsDNA DamageDrug Resistance, MultipleAntineoplastic AgentsHumansPaclitaxelReactive Oxygen SpeciesCell Line, TumorA549 CellsProteomics

Stichwörter der Autor:innen

Collateral sensitivityDNA damageMultidrug resistanceNon-small lung cancerPlatinum-based therapyTaxanes

Substanzen

PaclitaxelReactive Oxygen SpeciesAntineoplastic Agents

Autor:innen und Institutionen

  • i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal; Department of Biological Sciences, Faculty of Pharmacy of the University of Porto (FFUP), Porto, Portugal.
  • Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPO), Portuguese Oncology Institute (IPO Porto), Porto, Portugal; Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto,…
  • i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal; Associate Laboratory i4HB - Institute for Health and Bioeconomy, University Institute of Health Sciences - CESPU, Gandra, Port…
  • i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal; Department of Biological Sciences, Faculty of Pharmacy of the University of Porto (FFUP), Porto, Portugal. Electronic address:…

Förderung

  • Fundação para a Ciência e a Tecnologia
  • European Regional Development Fund

Zitieren

APA

Peixoto da Silva, S., Lara Santos, L., Xavier, C. P. R., & Vasconcelos, M. H. (2026). Multidrug resistant non-small cell lung cancer cells exhibiting collateral sensitivity to DNA damaging drugs. Life Sciences. https://doi.org/10.1016/j.lfs.2026.124273

Vancouver

Peixoto da Silva S, Lara Santos L, Xavier CPR, Vasconcelos MH. Multidrug resistant non-small cell lung cancer cells exhibiting collateral sensitivity to DNA damaging drugs. Life Sciences. 2026. doi:10.1016/j.lfs.2026.124273

BibTeX
@article{PeixotodaSilva2026,
  author = {Peixoto da Silva, Sara and Lara Santos, Lúcio and Xavier, Cristina P R and Vasconcelos, M Helena},
  title = {Multidrug resistant non-small cell lung cancer cells exhibiting collateral sensitivity to DNA damaging drugs},
  journal = {Life Sciences},
  year = {2026},
  doi = {10.1016/j.lfs.2026.124273}
}
Kostenlos starten →